Investigations of Dementia in Parkinson Disease
ConditionParkinsons
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorWashington University School of Medicine
About this trial
The purpose of this study is to use a brain imaging method called Pittsburgh B (PIB) Positron Emission Tomography (PET) and Vesicular Cholinergic Transport (VAT) PET to determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia.
Eligibility criteria
Qualifiers
PD patients must exhibit three of the following cardinal signs: rest tremor, rigidity, bradykinesia, or postural instability; or two of these features with one of the first three displaying asymmetry.
Disqualifiers
history of head trauma, major neurological or psychiatric diseases other than Parkinson disease and dementia, e.g. stroke, multiple sclerosis, depression or schizophrenia.
severe systemic diseases.
inability to lie still for 90 minutes.
metallic implants, pacemakers, or any other contraindication to MRI.
Trial design
Treatments tested in this trial
- PiB and VAT
Treatment groups
320 Participants
are divided into 2 treatment groupsSponsors and collaborators
Washington University School of Medicine
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov